Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5712997 | The Spine Journal | 2017 | 32 Pages |
Abstract
Imperfect placebos are ubiquitous in clinical trials of LP-SMT, and few trials have assessed for successful subject blinding or balanced expectations of treatment success between active and control group subjects. There is thus a strong potential for unmasking of control subjects, unequal non-specific effects between active and control groups, and non-inert placebos in existing trials. Future trials should consider assessing the success of subject blinding and ensuring inertness of their placebo a priori, as a minimum standard for quality.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Orthopedics, Sports Medicine and Rehabilitation
Authors
Aaron A. MSc, DC, Christine J PhD, DC, Jon B. PhD, Howard PhD, DC,